Screening for bladder cancer is not standard practice, but studies among populations with known risk factors suggest there may be a survival benefit.[46]Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan;37(1):3-13.
http://www.ncbi.nlm.nih.gov/pubmed/30105454?tool=bestpractice.com
[48]Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019 Feb;8(1):5-11.
https://tau.amegroups.com/article/view/21474/22804
http://www.ncbi.nlm.nih.gov/pubmed/30976562?tool=bestpractice.com
[92]Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006 Nov 1;107(9):2173-9.
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.22224
http://www.ncbi.nlm.nih.gov/pubmed/17029275?tool=bestpractice.com
US National Comprehensive Cancer Network guidelines recommend considering germline genetic testing for patients with an increased risk of Lynch syndrome, such as those who present at a younger age or with a personal or family history of a Lynch syndrome-related cancer (e.g., colorectal, endometrial, gastric, ovarian, pancreatic).[56]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric [internet publication].
https://www.nccn.org/guidelines/category_2
[61]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer [internet publication].
https://www.nccn.org/guidelines/category_1
Lynch syndrome is associated with increased risk of bladder cancer (estimated cumulative risk to aged 80 years: 2% to 7% with MLH1 variant; 4.4% to 12.8% with MSH2/EPCAM variants; 1% to 8.2% with MSH6 variant). Patients with MLH1 and MSH2 presented at an estimated average age of 59 years.[56]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric [internet publication].
https://www.nccn.org/guidelines/category_2